What We Do
Apalutamide plus abiraterone reduces risk of progression in mCRPC
Date: March/02/2021
ikrispharmanet
ikrispharmanet
02/March/2021
Look Like This Post !
Sign in to make your opinion count.
According to the final analysis from the phase 3 ACIS study came out during the 2021 Genitourinary Cancers Symposium, Adding apalutamide to abiraterone acetate 250 mg and prednisone reduced the risk of radiographic progression or death by 30% in patients with mCRPC receiving androgen deprivation therapy (ADT).
Get Maximum Result To Your Post - Share To All
Articles
Article Categories
USERONLINE
User online : 97
Leave a Comment
You must be logged in to post a comment.Login Here